

Peter Hohenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/171914/publications.pdf>

Version: 2024-02-01

80
papers

5,533
citations

201674

27
h-index

82547

72
g-index

81
all docs

81
docs citations

81
times ranked

6422
citing authors

#	ARTICLE	IF	CITATIONS
1	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2012, 379, 1879-1886.	13.7	1,752
2	One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1265.	7.4	832
3	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2â€³, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	10.7	288
4	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	12.8	237
5	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144.	12.8	197
6	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 2937-2943.	1.5	190
7	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	1.6	148
8	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	4.2	142
9	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	9.4	125
10	Postâ€relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transâ€Atlantic RPS Working Group. <i>Cancer</i> , 2017, 123, 1971-1978.	4.1	104
11	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
12	Angiosarcoma: State of the art and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 257-263.	4.4	95
13	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). <i>European Journal of Cancer</i> , 2017, 76, 60-67.	2.8	88
14	Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. <i>Journal of Surgical Oncology</i> , 1990, 44, 245-251.	1.7	84
15	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	4.1	71
16	Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. <i>BMC Public Health</i> , 2018, 18, 235.	2.9	64
17	Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. <i>Clinical and Translational Imaging</i> , 2017, 5, 183-197.	2.1	59
18	Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01). <i>Annals of Surgical Oncology</i> , 2016, 23, 1924-1927.	1.5	58

#	ARTICLE	IF	CITATIONS
19	Objective and Subjective Image Quality of Liver Parenchyma and Hepatic Metastases with Virtual Monoenergetic Dual-source Dual-energy CT Reconstructions. <i>Academic Radiology</i> , 2014, 21, 514-522.	2.5	56
20	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	1.6	56
21	Core needle biopsy versus incisional biopsy for differentiation of soft tissue sarcomas: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1917-1928.	4.1	46
22	Clinical Presentation of Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018, 34, 335-340.	1.3	42
23	Role of Surgery Combined with Kinase Inhibition in the Management of Gastrointestinal Stromal Tumor (GIST). <i>Annals of Surgical Oncology</i> , 2010, 17, 2585-2600.	1.5	39
24	Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma. <i>Cancer</i> , 2016, 122, 2624-2632.	4.1	38
25	Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years. <i>Oncology Research and Treatment</i> , 2020, 43, 613-619.	1.2	32
26	Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10031-10031.	1.6	32
27	Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). <i>European Journal of Cancer</i> , 2009, 45, 1103-1106.	2.8	31
28	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany – Cross-Sectional Results of a Nationwide Observational Study (PROSa). <i>Cancers</i> , 2020, 12, 3590.	3.7	31
29	Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. <i>American Journal of Pathology</i> , 2021, 191, 602-617.	3.8	30
30	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	4.3	29
31	MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸ Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1749-1755.	5.0	27
32	Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). <i>Radiation Oncology</i> , 2016, 11, 77.	2.7	22
33	Surgical interventions in patients with hematologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 83-91.	4.4	21
34	The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction. <i>World Journal of Surgical Oncology</i> , 2008, 6, 37.	1.9	21
35	Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018, 34, 359-365.	1.3	21
36	Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). <i>International Journal of Cancer</i> , 2019, 145, 2292-2303.	5.1	21

#	ARTICLE	IF	CITATIONS
37	Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. <i>Clinical Sarcoma Research</i> , 2018, 8, 12.	2.3	18
38	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
39	Primary and secondary angiosarcomas: a comparative single-center analysis. <i>Clinical Sarcoma Research</i> , 2015, 5, 14.	2.3	16
40	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 Cancers, 2021, 13, 1223.	3.7	15
41	Effect of dynamic seeding methods on the distribution of fibroblasts within human acellular dermis. <i>Cell and Tissue Banking</i> , 2015, 16, 605-614.	1.1	14
42	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSA Study. <i>Oncology Research and Treatment</i> , 2021, 44, 301-312.	1.2	13
43	Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?. <i>Lancet, The</i> , 2009, 373, 1058-1060.	13.7	12
44	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). <i>Annals of Surgical Oncology</i> , 2019, 26, 1332-1339.	1.5	12
45	Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF- κ B signalling. <i>Oncotarget</i> , 2017, 8, 89580-89594.	1.8	12
46	Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts. <i>European Journal of Surgical Oncology</i> , 2022, 48, 518-525.	1.0	12
47	Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group. <i>Cancers</i> , 2019, 11, 790.	3.7	11
48	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	4.5	11
49	Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy. <i>Cancers</i> , 2021, 13, 586.	3.7	10
50	Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSA study. <i>Supportive Care in Cancer</i> , 2022, 30, 187-196.	2.2	10
51	Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG). <i>Marine Drugs</i> , 2015, 13, 379-388.	4.6	9
52	Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). <i>BMJ Open</i> , 2016, 6, e009558.	1.9	9
53	Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe. <i>Visceral Medicine</i> , 2018, 34, 353-358.	1.3	8
54	Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study. <i>European Journal of Cancer</i> , 2019, 120, 47-53.	2.8	8

#	ARTICLE	IF	CITATIONS
55	The challenge of treating elderly patients with advanced bone and soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103108.	4.4	8
56	Definition and severity grading of postoperative lymphatic leakage following inguinal lymph node dissection. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 697-704.	1.9	8
57	Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET/CT Criteria. <i>American Journal of Roentgenology</i> , 2022, 218, 659-669.	2.2	8
58	Surgical Management and Minimally Invasive Approaches for the Treatment of Metastatic Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 457-464.	3.8	7
59	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). <i>European Journal of Cancer Care</i> , 2021, 30, e13484.	1.5	7
60	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa). <i>British Journal of Cancer</i> , 2022, 126, 1346-1354.	6.4	6
61	Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians. <i>Oncology Research and Treatment</i> , 2019, 42, 589-598.	1.2	5
62	First report on establishment and characterization of a carcinosarcoma tumour cell line model of the bladder. <i>Scientific Reports</i> , 2021, 11, 6030.	3.3	5
63	Computer tomography guided thoracoscopic resection of small pulmonary nodules in the hybrid theatre. <i>PLoS ONE</i> , 2021, 16, e0258896.	2.5	5
64	Accuracy and Safety of Ultrasound-Guided Core Needle Biopsy of Soft Tissue Tumors in an Outpatient Setting: A Sarcoma Center Analysis of 392 Consecutive Patients. <i>Cancers</i> , 2021, 13, 5659.	3.7	5
65	Career and Financial Situation of Patients Diagnosed with Soft Tissue Sarcomas. <i>Oncology Research and Treatment</i> , 2020, 43, 539-548.	1.2	4
66	The evaluation of circulating endothelial progenitor cells and related angiogenic markers as prognostic factors in soft-tissue tumors. <i>European Journal of Surgical Oncology</i> , 2018, 44, 496-501.	1.0	3
67	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11536-11536.	1.6	3
68	Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003334.	2.5	3
69	Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 240-241.	4.3	2
70	In vivo Quantification of the Effects of Radiation and Presence of Hair Follicle Pores on the Proliferation of Fibroblasts in an Acellular Human Dermis in a Dorsal Skinfold Chamber: Relevance for Tissue Reconstruction following Neoadjuvant Therapy. <i>PLoS ONE</i> , 2015, 10, e0125689.	2.5	2
71	Fusion imaging to evaluate the radiographic anatomical relationship between primary tumors and local recurrences in retroperitoneal soft tissue sarcoma. <i>Surgical Oncology</i> , 2020, 34, 109-112.	1.6	2
72	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	1.0	2

#	ARTICLE	IF	CITATIONS
73	Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study.. Journal of Clinical Oncology, 2018, 36, 11570-11570.	1.6	2
74	Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. Annals of Surgical Oncology, 2015, 22, 2815-2816.	1.5	1
75	Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from aPhaseA1 trial of the German Interdisciplinary Sarcoma Group (GISG 03). Strahlentherapie Und Onkologie, 2020, 196, 280-285.	2.0	1
76	Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study. Biology, 2021, 10, 639.	2.8	1
77	Trabectedin: adding clarification rather than novelty. Lancet Oncology, The, 2015, 16, 353-354.	10.7	0
78	Transplanted Fibroblasts Proliferate in Host Bronchial Tissue and Enhance Bronchial Anastomotic Healing in a Rodent Model. International Journal of Artificial Organs, 2017, 40, 515-521.	1.4	0
79	Selective internal radioembolization (SIRT) allows to control liver metastases of gastrointestinal stromal tumors (GIST) failing treatment with tyrosine kinase inhibitors (TKI).. Journal of Clinical Oncology, 2022, 40, 11540-11540.	1.6	0
80	Abstract 4139: Dual energy analysis of TKI response in GIST - results of a prospective trial. Cancer Research, 2022, 82, 4139-4139.	0.9	0